Cilnidipine, a Dual L/N-type Ca²⁺ Channel Blocker in Hypertension Management: A Review

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Calcium channel blockers (CCBs) are primary treatments for hypertension (HTN).
• Cilnidipine is a dihydropyridine calcium antagonist with dual N-type and L-type channel inhibition.
• Essential HTN management requires effective and well-tolerated antihypertensive agents.

Purpose of the Study:

• To evaluate the efficacy and safety of cilnidipine in treating mild to moderate essential HTN.
• To assess cilnidipine's impact on blood pressure, cardiovascular, renal, and neurological parameters.
• To compare cilnidipine's side effect profile with other CCBs, particularly regarding pulse rate and edema.

Main Methods:

• Review of clinical studies and pharmacological data on cilnidipine.
• Analysis of cilnidipine's mechanism of action on voltage-dependent calcium channels.
• Assessment of clinical outcomes including blood pressure reduction, organ protection, and adverse events.

Main Results:

• Cilnidipine demonstrates significant reduction in both systolic and diastolic blood pressure.
• It provides protection against hypertension-related cardiovascular and renal diseases.
• Unlike other CCBs, cilnidipine does not increase pulse rate and reduces pedal edema.

Conclusions:

• Cilnidipine is an effective antihypertensive agent for mild to moderate essential HTN.
• Its dual N-type and L-type calcium channel blockade offers unique benefits, including organ protection and a favorable side effect profile.
• Cilnidipine is a valuable monotherapy or add-on treatment option for hypertension management.